Market Overview The global Perjeta market was valued at USD 4.24 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2034. Perjeta (pertuzumab), a monoclonal antibody developed by Genentech, a subsidiary of Roche, plays a crucial role in treating HER2-positive breast cancer. The increasing burden of breast cancer cases globally,...